Stan Krulewicz - Concepedia

Author

Stan Krulewicz

GlaxoSmithKline (United States)ORCID

Also Known As

S Krulewicz, S. Krulewicz, S.P. Krulewicz, STAN KRULEWICZ, Stan Krulewicz, Stan P Krulewicz

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Duke Medical Center Duke University Hospital Pfizer (United States)McKesson (United States)

About

Stan Krulewicz is an author at GlaxoSmithKline (United States) specializing in medicine, psychiatry, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	717
2	Social Sciences	3	3	442
3	Public Health	1	1	90
4	Anesthesia	1	1	239
5	Gastroenterology	1	1	80

Stan Krulewicz

Publications

973

Citations

H-Index

Page 1

	Year	Citations
Effects of Paroxetine and Venlafaxine XR on Heart Rate Variability in Depression Jonathan Davidson, Lana L. Watkins, Michael J. Owens, Journal of Clinical Psychopharmacology Psychotropic MedicationPsychopharmacologyDepressed PatientsPharmacotherapySocial Sciences	2005	239
Paroxetine Treatment in Children and Adolescents With Major Depressive Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial Graham J. Emslie, Karen Dineen Wagner, Stan Kutcher, Journal of the American Academy of Child & Adolescent Psychiatry PsychiatryAdolescent MedicineMedicinePsychotropic MedicationPediatrics	2006	137
Paroxetine CR Augmentation for Posttraumatic Stress Disorder Refractory to Prolonged Exposure Therapy Naomi M. Simon, Kathryn M. Connor, Ariel J. Lang, The Journal of Clinical Psychiatry	2008	125
A Randomized, Controlled, Trial of Controlled Release Paroxetine in Fibromyalgia Ashwin A. Patkar, Prakash S. Masand, Stan Krulewicz, The American Journal of Medicine Interventional Pain MedicinePain MedicineMedicineControlled Release ParoxetinePharmacotherapy	2007	93
Differences in Medication Adherence and Healthcare Resource Utilization Patterns David V. Sheehan, Matthew Keene, Michael Eaddy, CNS Drugs Patient AdherenceHealth Care DeliveryPrimary CareHealth PolicyMedication Adherence	2008	90
A Double-Blind, Randomized, Placebo-Controlled Trial of Paroxetine Controlled-Release in Irritable Bowel Syndrome Prakash S. Masand, Chi‐Un Pae, Stan Krulewicz, Psychosomatics Functional Gastrointestinal DisorderPsychiatryGastrointestinal PharmacologyParoxetine Controlled-releaseMedicine	2009	80
Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine Michael J. Owens, Stan Krulewicz, Jeffrey S. Simon, Neuropsychopharmacology PsychiatryMedicinePsychotropic MedicationNorepinephrine Transporter InhibitionPsychopharmacology	2008	66
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial Mehmet Asım Bilen, Brian I. Rini, Martin H. Voss, Clinical Cancer Research	2021	32
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies Ibiayi Dagogo‐Jack, Antonello Abbattista, John F. Murphy, Journal of Thoracic Oncology	2022	29
Real-World Clinical Outcomes with First-Line Avelumab in Locally Advanced/metastatic Merkel Cell Carcinoma in the USA: SPEAR-Merkel C. Lance Cowey, Frank X. Liu, Ruth Kim, Future Oncology	2021	20

Page 1